This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

ADVANCE study (combination of an angiotensin converting enzyme inhibitor (ACEI) and a diuretic on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • ADVANCE study examined the effect of a fixed dose combination of an angiotensin converting enzyme inhibitor (ACEI) and a diuretic on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus
    • in the ADVANCE study the combination showed some benefits over placebo
    • RCT of 11,140 patients aged 55 years and older with type 2 diabetes
      • patients also had either a history of CV disease (including stroke and MI) or at least one other CV risk factor (e.g. age >= 65 years, smoking, history of major microvascular disease)
      • active treatment with a combination of perindopril and indapamide (initially 2mg/0.625mg, doubled to 4mg/1.25mg after 3 months) was compared with placebo
      • while taking the combination during the run-in phase, 1,737 other recruited patients withdrew, at least 29% of these due to adverse effects
      • primary endpoints were composites of major macrovascular events (death from CV disease, non-fatal stroke or non-fatal MI) and major microvascular events (new or worsening renal disease or new or worsening diabetic eye disease)
        • after 4.3 years, the combined endpoint of major macrovascular and microvascular events was reduced by 1.3% (number needed to treat [NNT]=77; relative risk reduction [RRR] 9%, 95%CI 0% to 17%; P=0.04)
        • death from CV disease was significantly reduced by 0.8% (NNT=125 over 4.3 years; RRR 18%, 95%CI 2% to 32%; P=0.03) and death from any cause was reduced by 1.2% (NNT= 83; RRR 14, 95%CI 2% to 25%; P=0.03)
    • significance of study
      • authors of the paper conclude that, “routine administration of a fixed combination of perindopril and indapamide to patients with type 2 diabetes was well tolerated and reduced the risks of major vascular events, including death”
      • however:
        • mean blood pressure in patients in the active arm was 5.6/2.2mmHg lower than that in patients in the placebo arm and this was highly statistically significant (p<0.0001)
          • therefore possible that the differences observed were an effect of lower blood pressure rather than any drug specific action
    • study adds to the body of evidence that lowering blood pressure in patients with type 2 diabetes reduces CV complications and deaths
    • also "..based on their safety, efficacy, tolerability and cost, thiazide diuretics are a good first choice agent for most people, including those with type 2 diabetes.." (2)

Reference:

  • (1) ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet 2007;370:829-40.
  • (2) MeReC Extra (November 2007); 30.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.